rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Harrow, Inc.

HROW · Nasdaq

Health CarePharmaceuticalsNot moving yet

HROW stood above a rising 150-day average in 22 of the last 52 weekly readings, and has been out of that trend for the last 13 weeks. It is 23.6% below that average now. Pharmaceuticals: 34% of its 74 stocks in an uptrend (−5 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 13
Industry in uptrend
34% -5 in 4 wk
Insider buys, 12 months
$937K
Insider sales, 12 months
$19.3M
Officials’ trades on record
0
Institutions holding
217 (+10)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 22 of 52 weeks.

22 Apr – 21 Oct
26%35%45%Apr 26Jun 26Jul 26Sep 26Oct 26

Pharmaceuticals: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$15.1M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months4
Sale orders, 12 months5
Buyers · sellers4 · 2
WhoDidSharesTraded
Amir ShojaeiCHIEF SCIENTIFIC OFFICERsold11,250at $40.0014 Aug 2026filed 17 Aug 2026
Lauren P. SilvernailDirectorbought1,000at $31.0018 May 2026filed 19 May 2026
Adrienne L. GravesDirectorbought1,000at $31.0718 May 2026filed 19 May 2026
Andrew R. BollPRESIDENT AND CFObought3,500at $29.9014 May 2026filed 15 May 2026
Mark L. BaumCHIEF EXECUTIVE OFFICERbought10,000at $30.2014 May 2026filed 15 May 2026
Opaleye Management Inc.10% ownersold134,000at $39.674 Mar 2026filed 5 Mar 2026
Opaleye Management Inc.10% ownersold4,263at $39.674 Mar 2026filed 5 Mar 2026
Opaleye Management Inc.10% ownersold59,000at $39.153 Mar 2026filed 5 Mar 2026
Opaleye Management Inc.10% ownersold1,309at $39.153 Mar 2026filed 5 Mar 2026
Opaleye Management Inc.10% ownersold5,000at $54.1827 Feb 2026filed 3 Mar 2026
Opaleye Management Inc.10% ownersold20,000at $53.356 Jan 2026filed 8 Jan 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders217+10 on the quarter
New · exited44 · 33
Reported value$919.8M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20262,740,117$116.4M+187,358+7.3%
Opaleye Management Inc.reduced · filed 14 Aug 20262,400,000$101.9M-432,230−15.3%
Private Capital Management, LLCadded · filed 14 Aug 20261,598,770$67.9M+36,770+2.4%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20261,417,212$60.2M+14,156+1.0%
Deep Track Capital, LPnew · filed 14 Aug 2026969,000$41.2M+969,000
STATE STREET CORPadded · filed 7 Aug 2026939,888$39.9M+84,841+9.9%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026905,560$38.5M+53,526+6.3%
BAMCO INCnew · filed 14 Aug 2026809,350$34.4M+809,350
DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 2026667,036$28.3M+87,516+15.1%
Jupiter Topco LLCnew · filed 14 Aug 2026579,127$24.6M+579,127
31 Mar 2023 – 30 Jun 2026
103158213Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Amir Shojaei Company insiderCHIEF SCIENTIFIC OFFICER · last 14 Aug 20260 · 1
Adrienne L. Graves Company insiderDirector · last 18 Jun 20261 · 0
Lauren P. Silvernail Company insiderDirector · last 18 Jun 20261 · 0
Perry J. Sternberg Company insiderDirector · last 18 Jun 20260 · 0
Andrew R. Boll Company insiderPRESIDENT AND CFO · last 14 May 20263 · 0
Mark L. Baum Company insiderCHIEF EXECUTIVE OFFICER · last 14 May 20266 · 0
Opaleye Management Inc. Company insider10% owner · last 4 Mar 202643 · 16
Patrick William Sullivan Company insiderCHIEF COMMERCIAL OFFICER · last 30 Jan 20260 · 0
Randall E. Pollard Company insiderCHIEF ACCOUNTING OFFICER · last 1 Sep 20250 · 0
John P. Saharek Company insiderCEO & President, ImprimisRx · last 7 Apr 20250 · 0
Martin A. Makary Company insiderDirector · last 14 Jun 20242 · 0
R. Lawrence Van Horn Company insiderDirector · last 21 Jun 20231 · 0

Same industry

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202575.1%
Operating profit marginFY 2025 · to 31 Dec 202511.2%
Free cash flow marginFY 2025 · to 31 Dec 202515.8%
Return on capital employedFY 2025 · to 31 Dec 202510.1%
Debt to equityFY 2025 · to 31 Dec 20254.77×
Research spendFY 2025 · to 31 Dec 20257.7%
Share count trendFY 2025 · to 25 Feb 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$72.9M
Free cash flowFY 2025 · to 31 Dec 2025$43.0M

Analyst forecasts

No analyst forecasts yet.